Estradiol (Bioidentical Estrogen) — Women's Hormones
Bioidentical 17β-estradiol for perimenopause and menopause hormone replacement therapy. FDA-approved with Grade A evidence.
Overview
Estradiol is the primary bioidentical estrogen used in hormone replacement therapy (HRT) for perimenopausal and menopausal women. It is FDA-approved for treating vasomotor symptoms (hot flashes, night sweats), genitourinary syndrome of menopause, and prevention of postmenopausal osteoporosis. Transdermal delivery (patch, gel, cream) is preferred over oral to minimize thrombotic risk and first-pass hepatic metabolism. The WHI follow-up studies and subsequent research confirm estrogen-only therapy has favorable risk-benefit profile, especially when initiated within 10 years of menopause onset (timing hypothesis).
Indications
- Vasomotor symptoms (hot flashes, night sweats)
- Genitourinary syndrome of menopause (vaginal dryness, dyspareunia)
- Prevention of postmenopausal osteoporosis
- Quality of life improvement during menopause transition
- Perimenopausal symptom management
Mechanism of Action
17β-estradiol delivered transdermally or orally enters systemic circulation
Dosing
| Compound | Dose | Frequency | Notes |
|---|---|---|---|
| Estradiol Patch | 0.025-0.1 mg/day | Change 1-2x weekly | Preferred delivery. Brands: Climara, Vivelle-Dot, Minivelle. Start 0.025-0.0375mg, titrate to symptom relief |
| Estradiol Gel | 0.25-1.0 mg/day | Apply daily | Brands: EstroGel, Divigel, Elestrin. Apply to arm or thigh. Start low, titrate based on symptom response |
| Estradiol Cream | 0.25-1.0 mg/day | Apply daily | Bi-est (80:20 estriol:estradiol) or pure estradiol. Apply to inner arm/thigh. Compounded allows custom dosing |
| Oral Estradiol | 0.5-2.0 mg/day | Once daily | Higher VTE risk vs transdermal. Use only if transdermal not tolerated. Brands: Estrace |
Safety & Contraindications
- Transdermal delivery (patch/gel/cream) preferred over oral to reduce VTE risk
- If uterus intact, MUST add progestogen for endometrial protection
- Contraindicated with active or history of breast cancer, VTE, stroke, liver disease
- Start at lowest effective dose and titrate based on symptoms
- Consider cardiovascular risk factors before initiation
- Breast cancer risk: Estrogen-only shows no increased risk in WHI (JAMA 2020)
- Best outcomes when started within 10 years of menopause (timing hypothesis)